Home›Trial›NCT05826535
🔬NCT05826535Phase 1Phase 2RECRUITING

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Study Summary

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.

Conditions
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin LymphomaLarge B-cell Lymphoma
Interventions / Drugs
Rondecabtagene autoleucel (ronde-cel)FludarabineCyclophosphamide
View on ClinicalTrials.gov ↗
Sponsor
LYEL
Lyell Immunopharma
Cell Therapy
D38/100
Study Details
Enrollment270 participants
Primary Completion—
Lead SponsorLyell Immunopharma, Inc.
Data Retrieved2026-04-11 04:20:24.455729+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.